Related Experiment Video
Updated: Aug 18, 2026
An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
New protection against Haemophilus influenzae type b infections in infants and young children
1Family and Community Health Graduate Nurse Practioner Program, University of Massachusetts, Lowell.
Insights
New Haemophilus influenzae type b (Hib) vaccines and updated immunization schedules, starting at 2 months, aim to prevent severe infant infections. Public health measures also support reducing pediatric morbidity and mortality from Hib.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Invasive Haemophilus influenzae type b (Hib) infections cause significant infant morbidity and mortality, particularly meningitis.
- Hib meningitis predominantly affects infants under 1 year of age.
Purpose of the Study:
- To detail the new Hib immunization schedule for children aged 2 months to 5 years.
- To outline public health strategies for preventing pediatric Hib infections.
Main Methods:
- Review of new vaccine data (HbOC, PRP-OMP).
- Analysis of updated immunization recommendations.
- Inclusion of public health prevention measures.
Main Results:
- Two new Hib vaccines (HbOC, PRP-OMP) are licensed for infant and child protection.
- New guidelines recommend initiating Hib immunization at 2 months of age.
- Comprehensive immunization schedules and public health strategies are presented.
Conclusions:
- Updated Hib immunization schedules and new vaccines significantly enhance protection against invasive Hib disease in infants and young children.
- Early initiation of vaccination (2 months) and adherence to the series are crucial.
- Public health initiatives are vital for controlling Hib-related pediatric morbidity and mortality.
Abstract:
Invasive Haemophilus influenzae type b (Hib) infections carry high morbidity and mortality, primarily due to meningitis among infants less than 1 year of age. Two new vaccines, HbOC and PRP-OMP, have been developed and licensed to prevent invasive Hib infections in infants and young children. New recommendations advise clinicians to begin immunization for Hib at 2 months of age and to complete the designated series. This article details the new Hib immunization schedule for all pediatric clients between 2 months and 5 years. Additionally, public-health measures toward the prevention of serious pediatric morbidity and mortality are covered.
Related Concept Videos
01:51Vaccinations
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:17Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:29Respiratory Syncytial Virus Disease